GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (XTER:IDP) » Definitions » Cash Flow from Others

Biogen (XTER:IDP) Cash Flow from Others : €553 Mil (TTM As of Dec. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Biogen Cash Flow from Others?

Biogen's cash flow from others for the three months ended in Dec. 2024 was €253 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Dec. 2024 was €553 Mil.


Biogen Cash Flow from Others Historical Data

The historical data trend for Biogen's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Cash Flow from Others Chart

Biogen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Others
Get a 7-Day Free Trial Premium Member Only Premium Member Only -540.63 999.17 -1,331.51 532.96 508.06

Biogen Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 132.78 118.04 82.03 99.47 253.27

Biogen Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €553 Mil.

Biogen Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Biogen's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Biogen Headlines

No Headlines